TRT vs BHRT vs Peptide — Clinical Decision Support
Hormone replacement (TRT/BHRT) and peptide pathways are not mutually exclusive — candidacy depends on biomarkers, fertility goals, age, and symptom profile. This decision-support comparison maps the routing logic used in provider review.
Hormone replacement is decisive when biomarkers confirm deficiency and the patient is a candidate after full review.
Explore pathwayPeptide pathway is decisive when axis support, recovery, or non-suppressive optimization is the goal — or as the first step when biomarkers are borderline.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Does the assessment route me?
Yes — the adaptive assessment maps your biomarkers, symptoms, and goals to candidate pathways under provider review.
Can I move between pathways?
Yes — pathway selection is reviewed at each recalibration cadence.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment